KYLE KIMBROUGH: Open Payments
NPI 1104231695 · NEW ALBANY, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$351 in 20 payments from 12 companies in 2025. Trend: 2023 $1,245 · 2024 $808 · 2025 $351
Food & beverage: $351
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $57 |
| Boston Scientific Corporation | 2 | $44 |
| Amgen Inc. | 2 | $36 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $34 |
| Lilly USA, LLC | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| ABBVIE INC. | 2 | $29 |
| Merck Sharp & Dohme LLC | 1 | $25 |
| Stryker Corporation | 1 | $19 |
| Exact Sciences Corporation | 1 | $18 |
Products named: JARDIANCE, MOUNJARO, TRINTELLIX, Saxenda, GARDASIL 9, General - Therapies, WaveWriter Alpha Prime 16, EVENITY.
Industry payments across MS — which companies pay providers there.
